Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Foamix Announces Closing of its Follow-on Offering of Ordinary Shares and Full Exercise of its Option by the Underwriters
-
Foamix (FOMX) Prices 11.67M Share Follow-On Offering at $6/Sh
-
Foamix Announces Pricing of its Follow-on Offering of Ordinary Shares
-
Foamix (FOMX) Announces Proposed Follow-On Share Offering
-
Foamix Announces Proposed Follow-on Offering of Ordinary Shares
-
Foamix Pharmaceuticals to Present at the Cowen & Company 38th Annual Health Care Conference
-
Foamix Pharmaceuticals to Present at the Cowen & Company 37th Annual Healthcare Conference
-
Foamix (FOMX) Prices 6M Ordinary Shares Offering for Proceeds of ~$57M
-
Foamix Pharmaceuticals Ltd. Announces Pricing of its $57 Million Follow-on Offering of Ordinary Shares
-
Foamix (FOMX) Announces Ordinary Shares Offering
-
Foamix Pharmaceuticals Ltd. Announces Proposed Follow-on Offering of Ordinary Shares
-
Foamix to Present Corporate Overview at the 36th Annual Cowen & Company Healthcare Conference
-
Ovid Therapeutics Announces Appointment of Dr. Anna Kazanchyan to Senior Vice President, Business Development
-
Fresh Off Generic Sale, Allergan (AGN) is Poised for Merger of Epic Proportions (AMGN) (ABBV)
-
Foamix Pharmaceuticals Ltd. Announces Closing of Its $69 Million Public Offering of Ordinary Shares
-
Foamix Pharmaceuticals Ltd. Announces Closing of Its $69 Million Public Offering of Ordinary Shares
-
Notable Analyst Rating Changes 4/16: (COH) (INTC) (LOW) Upgraded; (AGCO) (NOK) (TRQ) Downgraded
-
Foamix (FOMX) Pices Larger 6.45M Common Offering at $9.30/Share
-
Foamix Pharmaceuticals Ltd. Announces Upsizing and Pricing of Its $60 Million Public Offering of Ordinary Shares
-
Foamix Pharmaceuticals Ltd. Announces Upsizing and Pricing of Its $60 Million Public Offering of Ordinary Shares
-
Foamix Pharmaceuticals Ltd. Files Registration Statement for Proposed Follow-On Offering
-
Foamix Pharmaceuticals Ltd. Files Registration Statement for Proposed Follow-On Offering
-
Foamix to Present Corporate Overview at the Cowen & Company 35th Annual Health Care Conference
-
Notable Analyst Rating Changes 10/13: (NAVI) (VRTX) (SFUN) Upgraded; (JCP) (ONNN) (PBF) Downgraded
-
UPDATE: Cowen Starts Foamix Pharmaceuticals (FOMX) at Buy
-
Pre-Open Stock Movers 10/13: (IBIO) (APL) (ALNY) Higher; (ALCS) (GTAT) (LAD) Lower (more...)
-
Foamix Pharmaceuticals (FOMX) IPO Opens Sharply Higher; Pauses on Volatility
-
Foamix Pharmaceuticals (FOMX) Prices 6.7M IPO at $6/Share

